Skip to main content

Advertisement

SpringerLink
Log in

Improving Survival of Pancreatic Cancer. What Have We Learnt?

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Pancreatic adenocarcinoma still ranks high among cancer-related deaths worldwide. In spite of substantial strides in preoperative staging, surgery, perioperative care, and adjuvant treatment, the survival still remains dismal. A number of patient-, disease-, and surgeon-related factors play a role in deciding the eventual outcome of the patient. The aim of this commentary is to review the current knowledge of various factors and the recent advances that impact the survival of patients with pancreatic adenocarcinoma. A search of scientific literature using Embase and MEDLINE, for the years 1985–2015, was carried out for search terms “pancreatic cancer” and “survival.” Further search was based on the various specific prognostic factors that contribute towards survival of patients with pancreatic cancer found in the literature. Most of the studies used for this review include those that deal with pancreatic head cancers, some include patients with pancreatic cancers in all locations while very few included patients with tumors of body and tail only. In spite of significant developments in pre- and perioperative management, increased rates of margin-negative resections, and use of adjuvant treatment, the survival rates of pancreatic cancer patients remains poor. A paradigm shift with more effective adjuvant regimen and genetic interventions may help change the outcomes of patients with pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perysinakis I, Avlonitis S, Georgiadou D (2015) Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer. ANZ J Surg 85(3):183–186

    Article  PubMed  Google Scholar 

  2. Millikan KW, Deziel DJ, Silverstein JC et al (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65:618–623, discussion 23–4

    PubMed  CAS  Google Scholar 

  3. Cameron JL, Pitt HA, Yeo CJ et al (1993) One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217:430–435, discussion 5–8

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Schnelldorfer T, Ware AL, Sarr MG et al (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247:456–462

    Article  PubMed  Google Scholar 

  5. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69

    Article  PubMed  Google Scholar 

  6. Hariharan D, Saied A, Kocher HM (2008) Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 10:58

    Article  CAS  Google Scholar 

  7. Ries LA, Eisner MP, Kosary CL et al (2000) SEER cancer statistics review, 1973–1996. National Cancer Institute, Bethesda

    Google Scholar 

  8. Nitecki SS, Sarr MG, Colby TV et al (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221(1):59–66

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Winter JM, Brennan MF, Tang LH et al (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol 19:169–175

    Article  PubMed  Google Scholar 

  10. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210

    Article  PubMed  CAS  Google Scholar 

  11. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277

    Article  PubMed  CAS  Google Scholar 

  12. Begg CB, Cramer LD, Hoskins WJ et al (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747–1751

    Article  PubMed  CAS  Google Scholar 

  13. Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10:1199–1210

    Article  PubMed  Google Scholar 

  14. Grobmyer SR, Pieracci FM, Allen PJ et al (2007) Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg 204:356–364

    Article  PubMed  Google Scholar 

  15. Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74

    Article  PubMed  PubMed Central  Google Scholar 

  16. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Trede M, Richter A, Wendl K (2001) Personal observations, opinions, and approaches to cancer of the pancreas and the periampullary area. Surg Clin N Am 81:595–610

    Article  PubMed  CAS  Google Scholar 

  18. Yeo CJ, Cameron JL, Lillemoe KD et al (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221:721–731, discussion 31–3

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Allison DC, Piantadosi S, Hruban RH et al (1998) DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 67:151–159

    Article  PubMed  CAS  Google Scholar 

  20. Riall TS, Cameron JL, Lillemoe KD et al (2006) Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140:764–772

    Article  PubMed  Google Scholar 

  21. Hoffman JP, Lipsitz S, Pisansky T et al (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317

    PubMed  CAS  Google Scholar 

  22. Staley CA, Lee JE, Cleary KR et al (1996) Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171:118

    Article  PubMed  CAS  Google Scholar 

  23. Pisters PW, Abbruzzese JL, Janjan NA et al (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843

    PubMed  CAS  Google Scholar 

  24. Pisters PW, Wolff RA, Janjan NA et al (2002) Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20:2537

    Article  PubMed  CAS  Google Scholar 

  25. Assifi MM, Lu X, Eibl G et al (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150:466

    Article  PubMed  PubMed Central  Google Scholar 

  26. Andriulli A, Festa V, Botteri E et al (2012) Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 19:1644

    Article  PubMed  Google Scholar 

  27. Gillen S, Schuster T, Meyer Zum Büschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7, e1000267

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035–1046, Epub 2006 Jul 24

    Article  PubMed  Google Scholar 

  29. Lopez NE, Prendergast C, Lowy AM (2014) Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol 20(31):10740–10751

    Article  PubMed  PubMed Central  Google Scholar 

  30. Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer the importance of this emerging stage of disease. J Am Coll Surg 206(5):833–846, discussion 846–8

    Article  PubMed  Google Scholar 

  31. Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727

    Article  PubMed  Google Scholar 

  32. NCCN National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org

  33. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas.In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds.Cancer Medicine.6th ed.Hamilton, Ontario, Canada: American Cancer Society + BC Decker Inc, 2003: 1585614

  34. Li D, Xie K, Wolff RA et al (2004) Pancreatic cancer. Lancet 363(9414):1049–1057

    Article  PubMed  CAS  Google Scholar 

  35. Greer SE, Pipas JM, Sutton JE et al (2008) Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 206:451

    Article  PubMed  Google Scholar 

  36. Stokes JB, Nolan NJ, Stelow EB et al (2011) Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 18:619

    Article  PubMed  Google Scholar 

  37. Ammori JB, Colletti LM, Zalupski MM et al (2003) Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7:766

    Article  PubMed  Google Scholar 

  38. Pipas JM, Barth RJ Jr, Zaki B et al (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995

    Article  PubMed  Google Scholar 

  39. Palmer DH, Stocken DD, Hewitt H et al (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14:2088

    Article  PubMed  Google Scholar 

  40. Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903

    Article  PubMed  CAS  Google Scholar 

  41. Kosuge T, Kiuchi T, Mukai K, Kakizoe T, Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP) (2006) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36:159–165

    Article  PubMed  Google Scholar 

  42. Smeenk HG, van Eijck CH, Hop WC et al (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246:734–740

    Article  PubMed  Google Scholar 

  43. Takada T, Amano H, Yasuda H, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695

    Article  PubMed  Google Scholar 

  44. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073

    Article  PubMed  CAS  Google Scholar 

  45. Uesaka K, Fukutomi A, Boku N, et al (2012) Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study) (abstract). J Clin Oncol 30:(suppl 34; abstr 145)

  46. Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576

    Article  PubMed  CAS  Google Scholar 

  47. Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  48. Sindelar WF, Kinsella TJ (1999) Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 10(Suppl 4):226

    Article  PubMed  Google Scholar 

  49. Hishinuma S, Ogata Y, Matsui J, Ozawa I (1998) Results of surgery and adjuvant radiotherapy for pancreatic cancer. J Hepatobiliary Pancreat Surg 5:143

    Article  PubMed  CAS  Google Scholar 

  50. Hosotani R, Kogire M, Arii S et al (1997) Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 44:1528

    PubMed  CAS  Google Scholar 

  51. Seufferlein T, Bachet JB, Van Cutsem E et al (2012) Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii33

    Article  PubMed  Google Scholar 

  52. Karpoff HM, Klimstra DS, Brennan MF, Conlon KC (2001) Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 136:44

    Article  PubMed  CAS  Google Scholar 

  53. Dresler CM, Fortner JG, McDermott K, Bajorunas DR (1991) Metabolic consequences of (regional) total pancreatectomy. Ann Surg 214:131

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  54. Brooks JR, Brooks DC, Levine JD (1989) Total pancreatectomy for ductal cell carcinoma of the pancreas. An update. Ann Surg 209:405

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  55. Kneuertz PJ, Pitt HA, Bilimoria KY et al (2012) Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 16:1727

    Article  PubMed  Google Scholar 

  56. Reddy S, Wolfgang CL, Cameron JL et al (2009) Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg 250:282

    Article  PubMed  Google Scholar 

  57. Nathan H, Wolfgang CL, Edil BH et al (2009) Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol 99:87

    Article  PubMed  Google Scholar 

  58. Kalser MH, Barkin J, MacIntyre JM (1985) Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 56:397–402

    Article  PubMed  CAS  Google Scholar 

  59. Benassai G, Mastrorilli M, Mosella F, Mosella G (1999) Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 18:23–28

    PubMed  CAS  Google Scholar 

  60. Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ferrone CR, Kattan MW, Tomlinson JS et al (2005) Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 23:7529

    Article  PubMed  PubMed Central  Google Scholar 

  62. Tomlinson JS, Jain S, Bentrem DJ et al (2007) Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 142:767.79

    Article  Google Scholar 

  63. Ishikawa O, Ohhigashi H, Sasaki Y et al (1988) Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208:215

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  64. Tsuchiya R, Tsunoda T, Yamaguchi T (1990) Operation of choice for resectable carcinoma of the head of the pancreas. Int J Pancreatol 6:295

    PubMed  CAS  Google Scholar 

  65. Stojadinovic A, Brooks A, Hoos A et al (2003) An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 196:954

    Article  PubMed  Google Scholar 

  66. Manabe T, Ohshio G, Baba N et al (1989) Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 64:1132–1137

    Article  PubMed  CAS  Google Scholar 

  67. Satake K, Nishiwaki H, Yokomatsu H et al (1992) Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 175:259–265

    PubMed  CAS  Google Scholar 

  68. Kawarada Y, Yokoi H, Isaji S et al (1999) Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer. Digestion 60(Suppl 1):120–125

    Article  PubMed  Google Scholar 

  69. Nagakawa T (1996) Pancreaticoduodenectomy Geka Shinryo 38:437–444

    Google Scholar 

  70. Hanyu F, Imaizumi T, Nakasako T et al (1995) Pancreatic cancer. Gastroenterol Surg 18:323–330

    Google Scholar 

  71. Pedrazzoli S, DiCarlo V, Dionigi R et al (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228:508

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236:355

    Article  PubMed  PubMed Central  Google Scholar 

  73. Farnell MB, Pearson RK, Sarr MG et al (2005) A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138:618

    Article  PubMed  Google Scholar 

  74. Chua TC, Saxena A (2010) Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 14(9):1442–1452

    Article  PubMed  Google Scholar 

  75. Fortner JG (1973) Regional resection of cancer of the pancreas: a new surgical approach. Surgery 73:307–320

    PubMed  CAS  Google Scholar 

  76. Leach SD, Lee JE, Charnsangavej C et al (1998) Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85:611

    Article  PubMed  CAS  Google Scholar 

  77. Fuhrman GM, Leach SD, Staley CA et al (1996) Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 223:154

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  78. Murakami Y, Uemura K, Sudo T et al (2013) Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. J Surg Oncol 107:414

    Article  PubMed  Google Scholar 

  79. Tseng JF, Raut CP, Lee JE et al (2004) Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8:935

    Article  PubMed  Google Scholar 

  80. Raut CP, Tseng JF, Sun CC et al (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52

    Article  PubMed  PubMed Central  Google Scholar 

  81. Martin RC 2nd, Scoggins CR, Egnatashvili V et al (2009) Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg 144:154

    Article  PubMed  Google Scholar 

  82. Ramacciato G, Mercantini P, Petrucciani N et al (2009) Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 16:817

    Article  PubMed  Google Scholar 

  83. Castleberry AW, White RR, De La Fuente SG et al (2012) The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol 19:4068

    Article  PubMed  Google Scholar 

  84. Nakagohri T, Kinoshita T, Konishi M et al (2003) Survival benefits of portal vein resection for pancreatic cancer. Am J Surg 186(2):149–153

    Article  PubMed  Google Scholar 

  85. Evans DB, Farnell MB, Lillemoe KD et al (2009) Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16:1736

    Article  PubMed  Google Scholar 

  86. Martin RCG 2nd, Scoggins CR, Egnatashvili V et al (2009) Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg 144:154–159

    Article  PubMed  Google Scholar 

  87. Yekebas EF, Bogoevski D, Cataldegirmen G et al (2008) En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and longterm survival in 136 patients. Ann Surg 247:300–309

    Article  PubMed  Google Scholar 

  88. Stitzenberg KB, Watson JC, Roberts A et al (2008) Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 15:1399–1406

    Article  PubMed  Google Scholar 

  89. Mollberg N, Rahbari NN, Koch M et al (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 254(6):882–893

    Article  PubMed  Google Scholar 

  90. Sosa JA, Bowman HM, Gordon TA et al (1998) Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 228(3):429–438

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  91. Lieberman MD, Kilbum H, Lindsey M et al (1995) Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 222(5):638–645

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  92. Glasgow RE, Mulvihill SJ (1996) Relation of hospital volume to outcome in patients undergoing Whipple resection for adenocarcinoma in Northern California hospitals in 1993. Presented at The Pancreas Club, Inv. 30th Annual Meeting, San Francisco

  93. Center for the Assessment and Management of Change in Academic Medicine (1998) Outcomes of complex, high-risk surgical procedures at high, moderate, and low volume hospitals: the example of Whipple’s procedure. AAMC Fact Sheet 2(3)

  94. (1995) Health Care Financing Administration, OACT, Office of National Health Statistics. DRIVMcGraw-Hill HCC

  95. Hannan EL, O’Donnell JF, Kilburn H et al (1989) Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. JAMA 262(4):503–510

    Article  PubMed  CAS  Google Scholar 

  96. Luft HS, Bunker JP, Enthoven AC (1979) Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 301(25):1364–1369

    Article  PubMed  CAS  Google Scholar 

  97. Birkmeyer JD, Siewers AE, Finlayson EV et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128

    Article  PubMed  Google Scholar 

  98. Gooiker GA, van Gijn W, Wouters MW et al (2011) Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 98:485

    Article  PubMed  CAS  Google Scholar 

  99. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  100. Mayo SC, Gilson MM, Herman JM et al (2012) Management of patients with pancreatic adenocarcinoma national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 214:33–45

    Article  PubMed  PubMed Central  Google Scholar 

  101. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  102. Balakrishnan A, Bleeker FE, Lamba S et al (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67:3545–3550

    Article  PubMed  CAS  Google Scholar 

  103. Iacobuzio-Donahue CA (2011) Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut

  104. Hruban RH, van Mansfeld AD, Offerhaus GJ et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545

    PubMed  CAS  PubMed Central  Google Scholar 

  105. Almoguera C, Shibata D, Forrester K et al (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549

    Article  PubMed  CAS  Google Scholar 

  106. Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140

    PubMed  CAS  Google Scholar 

  107. Jimenez RE, Warshaw AL, Z’graggen K et al (1999) Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 230:501

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  108. Shi C, Fukushima N, Abe T et al (2008) Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 7:353

    Article  PubMed  CAS  Google Scholar 

  109. Kondo H, Sugano K, Fukayama N et al (1997) Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 79:900

    Article  PubMed  CAS  Google Scholar 

  110. Caldas C, Hahn SA, Hruban RH et al (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:3568

    PubMed  CAS  Google Scholar 

  111. Yachida S, White CM, Naito et al (2012) Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 18(22):6339–6347

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  112. Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806–1813

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  113. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC et al (2002) DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 20:4531–4542

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of GI Surgery, GI Oncology, Minimal Access and Bariatric Surgery, Medanta, The Medicity Hospital, Gurgaon, 122001, India

    Tanveer Singh & Adarsh Chaudhary

Authors
  1. Tanveer Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adarsh Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adarsh Chaudhary.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, T., Chaudhary, A. Improving Survival of Pancreatic Cancer. What Have We Learnt?. Indian J Surg 77, 436–445 (2015). https://doi.org/10.1007/s12262-015-1368-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-015-1368-7

Keywords

Search

Navigation